The new knowledge that RBCs perform low levels of protein synthesis could also be therapeutically useful; thus, drugs enabling stop codon readthrough might be useful for patients with beta-thalassemia who have premature stop codons in their beta-globin gene (Kar et al., 2020; Kumar et al., 2022). This evidence concerns the gene HBB and beta thalassemia.